To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
This bill would nullify the Department of Health and Human Services’ final rule titled “Medications for the Treatment of Opioid Use Disorder,” with one exception: the portion of the rule that concerns accreditation of opioid treatment programs would remain in effect. In practical terms, all of the rule’s provisions governing how medications for treating opioid use disorder are regulated, delivered, or overseen would lose force, while the accreditation requirements for opioid treatment programs (OTPs) would continue to apply. The change would effectively revert regulatory authority over MAT (medications used to treat opioid use disorder) to the status quo prior to the final rule, potentially slowing or reversing updates intended to standardize treatment practices and access.
Key Points
- 1The bill would strike down or nullify the final rule’s provisions related to medications for treating opioid use disorder.
- 2The only portion of the final rule that would remain in effect is the section relating to accreditation of opioid treatment programs.
- 3This would revert federal regulation of MAT away from the final rule’s standards, likely restoring prior regulatory requirements.
- 4Accreditation requirements for OTPs would continue to apply, potentially maintaining oversight and quality standards for those facilities.
- 5The bill’s impact depends on how pre-rule framework compares to the final rule; overall access to and administration of MAT could be affected.